About CAEREGEN THERAPEUTICS LLC
RetiNova Therapeutics is developing the first regenerative therapy for retinal ischemic diseases, focusing on reversing vision loss through the Noregen™ program, which mimics the natural protein norrin to regenerate retinal tissue and restore vision.
Development of regenerative therapies for retinal ischemic diseasesPreclinical development of Noregen™ (CTR-107), a synthetic protein modeled after norrinRestoration of the blood-retina barrier and regeneration of retinal vasculatureActivation of progenitor stem cells for vascular and neuronal growthCounteracting VEGF-induced retinal edema and preventing fibrosis
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to CAEREGEN THERAPEUTICS LLC right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.